Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PRKAR1B antisense RNA 2 (PRKAR1B-AS2)
- Target
- PRKAR1B-AS2
- Molecular classification
- Long noncoding RNA (lncRNA), Other
01
Overview
PRKAR1B antisense RNA 2 (PRKAR1B-AS2) is a long noncoding RNA transcribed antisense to the protein-coding gene PRKAR1B on chromosome 7. It is overexpressed in ovarian cancer, where it promotes tumor cell proliferation, migration, invasion, and chemoresistance (notably to cisplatin and alpelisib) by modulating the PI3K/AKT/mTOR pathway, primarily through direct interaction with PI3K-110α. Knockdown of PRKAR1B-AS2 inhibits these processes and enhances chemosensitivity in both in vitro and animal xenograft models, highlighting its potential as both a therapeutic target and a biomarker for cancer progression and drug resistance
- Other names
- AC147651.5
02
Mechanism of action
Targeting PRKAR1B-AS2 (e.g., by small interfering RNA) leads to downregulation of PI3K-110α and inhibition of PI3K/AKT/mTOR pathway signaling, enhancing sensitivity to cisplatin and alpelisib in ovarian cancer models
03
Biological functions
Regulation of PI3K/AKT/mTOR signalingPromotion of tumorigenesisChemoresistance modulation (e.g., cisplatin resistance)Regulation of cell proliferation, migration, and invasion
04
Disease associations
Cancer (notably ovarian cancer)Chemoresistance (cisplatin and alpelisib)
05
Safety considerations
Potential off-target effects and delivery challenges of siRNA or antisense oligonucleotides targeting lncRNAs
06
Interacting drugs
Cisplatin
1 more in the full profile.
07
Biomarkers
PRKAR1B-AS2 expression as a potential prognostic biomarker for overall survival and chemoresistance in ovarian cancer
Beyond the preview
Go deeper on PRKAR1B antisense RNA 2 (PRKAR1B-AS2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRKAR1B antisense RNA 2 (PRKAR1B-AS2).